MARKET

LXEO

LXEO

Lexeo Therapeutics Inc
NASDAQ
3.185
-0.125
-3.78%
Opening 12:49 09/28 EDT
OPEN
3.270
PREV CLOSE
3.310
HIGH
3.290
LOW
3.160
VOLUME
369.13K
TURNOVER
--
52 WEEK HIGH
10.99
52 WEEK LOW
3.160
MARKET CAP
261.32M
P/E (TTM)
-2.7538
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LXEO last week (0921-0925)?
Weekly Report · 6h ago
Leerink Partners Keeps Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)
TipRanks · 5d ago
Lexeo Therapeutics Price Target Maintained With a $15.00/Share by Leerink Partners
Dow Jones · 5d ago
Lexeo Therapeutics Is Maintained at Outperform by Leerink Partners
Dow Jones · 5d ago
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Lexeo Therapeutics, Inc. (LXEO) and Edgewise Therapeutics (EWTX)
TipRanks · 5d ago
Press Release: Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX(TM) for Program Designed to Treat Friedreich Ataxia
Dow Jones · 5d ago
Lexeo Expands Friedreich Ataxia Pipeline Through Mantle Deal, New Collaborations
NASDAQ · 6d ago
Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Benzinga · 6d ago
More
About LXEO
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).

Webull offers Lexeo Therapeutics Inc stock information, including NASDAQ: LXEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXEO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LXEO stock methods without spending real money on the virtual paper trading platform.